Aug 26, 2024
Akebia Therapeutics to Present at Upcoming Investor Conferences
Jul 01, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 25, 2021
Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates
Feb 18, 2021
Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors
Feb 08, 2021
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights
Feb 02, 2021
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 02, 2020
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 24, 2020
Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 18, 2020
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500(TM)
Nov 05, 2020
Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates
Oct 26, 2020
Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights
Oct 22, 2020
Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Oct 09, 2020
Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined
Sep 08, 2020
Akebia Therapeutics Announces September 2020 Investor Conference Schedule
Sep 03, 2020
Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis
Aug 26, 2020
Akebia Therapeutics Announces First Commercial Launch of VAFSEO(TM) (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan
Aug 10, 2020
Akebia Reports Second Quarter 2020 Financial Results
Aug 04, 2020
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 03, 2020
Akebia Therapeutics to Report Second Quarter 2020 Financial Results
Jul 14, 2020
Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19